Legend Biotech (LEGN) Tops Q2 EPS by 15c

Legend Biotech (NASDAQ: LEGN) reported Q2 EPS of $0.03, $0.15 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $255.06 million versus the consensus estimate of $234.23 million.

For earnings history and earnings-related data on Legend Biotech (LEGN) click here.

You May Also Be Interested In

• Ericsson (ERIC) Tops Q2 EPS by 3c
• Asana (ASAN) Reiterated at Market Outperform by Citizens Post Investor Chat
• USA Today (TDAY) PT Raised to $10 at Citizens as In-Line Results Expected